Overview

* Nautilus Q3 operating expenses decreased 19% yr/yr due to operating efficiencies

* Net loss for Q3 was $13.6 mln, down from $16.4 mln in prior year period

* Company holds $168.5 mln in cash, cash equivalents, and investments as of Sept 30, 2025

Outlook

* Nautilus plans to launch early access program for Tau proteoforms in H1 2026

* Company targets full commercial launch of proteome platform in late 2026

Result Drivers

* TAU PROTEOFORMS - Progress in processing Tau proteoform samples for product validation and publications, with data to be shared at World HUPO conference

* NEW ASSAY DEVELOPMENT - Development of new broadscale assay format to support commercial launch in late 2026

* OPERATING EFFICIENCIES - Decrease in operating expenses attributed to efficiencies, lower development costs, and decreased salaries and compensation

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.11

Q3 Net -$13.57

Income mln

Q3 $15.47

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Nautilus Biotechnology Inc ( NAUT ) is $2.50, about 46% above its October 27 closing price of $1.35

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)